CompaniesProteon Therapeutics

Proteon Therapeutics

defunct

About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (8)

Total Trials

8

As Lead Sponsor

8

As Collaborator

0

Total Enrollment

1,394

By Phase

PHASE1: 3PHASE3: 2PHASE2: 1PHASE1/PHASE2: 2

By Status

COMPLETED: 7WITHDRAWN: 1

Clinical Trials Pipeline7 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

Today

Hover over trial bars to see details

Recent Trials

NCT02956993Lead Sponsor

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

PHASE1Completed

29 participants

Started: Nov 30, 2016 · Completed: Apr 30, 2019

NCT02414841Lead Sponsor

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

PHASE3Completed

696 participants

Started: Aug 31, 2015 · Completed: May 1, 2019

NCT02110901Lead Sponsor

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

PHASE3Completed

349 participants

Started: Jul 31, 2014 · Completed: Dec 31, 2018

NCT01616290Lead Sponsor

Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

PHASE1Completed

14 participants

Started: Oct 31, 2012 · Completed: Jul 31, 2015

NCT01305824Lead Sponsor

A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

PHASE2Completed

151 participants

Started: Mar 31, 2011 · Completed: Nov 30, 2012

View all 8 trials →

Funding History (20)

8-K

Aug 11, 2025

8-K

Jun 12, 2025

8-K

May 8, 2025

8-K

Apr 28, 2025

DEFA14A

Apr 25, 2025

DEF 14A

Apr 25, 2025

8-K

Mar 5, 2025

8-K

Jan 13, 2025

8-K

Dec 11, 2024

8-K

Dec 5, 2024

Related Companies

Artara Therapeutics

acquired